Slide 1: Year-End Report Q4 2024
Year-End Report Q4 2024 Telephone Conference - 12th of February 2025 09:30 Theresa Agnew. CEO Alexander Kotsinas. CFO
Slide 2: Executive Summary Q4 2024
EXECUTIVE SUMMARY Q4 - 2024 • Sales were 365 MSEK (+23%) • Sales in EMEA increased by 24% and in APAC sales increased by 10%. Americas increased by 32% • EBIT 103 MSEK (+28%) and EBIT margin 28% (27%)
Slide 3: Key Events
Key Events • The Board proposes an ordinary dividend according to policy of SEK 1.95 (1.90) per share, plus an extra dividend of SEK 4.95 (5.00) per share resulting in a total dividend of SEK 6.90 (6.90) per share, corresponding to SEK 698.0 million (696.8) • November 4: Anatom Holding AG, a Switzer
Slide 4: Launches
Launches Distributor Country Product Abbott Mexico Prodentis mint lozenges Agefinsa El Salvador Prodentis apple lozenges BioGaia Finland BioGaia Gastrus Pure Action capsules Ewopharma Romania BioGaia Pharax drops Ewopharma Czech Republic BioGaia Pharax drops Ewopharma Slovenia BioGaia Pharax drops E
Slide 5: Sales per Segment
Sales per Segment Sales per Segment Q4 2024 1% • Total sales for the quarter increased by 23% 25% • Pediatrics sales increased by 23% due to increased sales of Protectis Drops. Sales increased mainly in Americas and EMEA. Sales increased in Brazil, USA and UK • Adult sales increased by 20% mainly du
Slide 6: Sales per Region
Sales per Region Sales per Region Q4 2024 • EMEA: sales increased by 24% mainly in UK, Belgium and Spain • APAC: sales increased by 10% mainly in South Korea, Japan and Vietnam 31% 40% • Americas: sales increased by 32% mainly in BioGaia USA, Brazil and Canada 29% YTD 2024 38% Q4 Q4 YTD YTD 36% MSEK
Slide 7: Financials
Alexander Kotsinas, CFO Financials 7
Slide 8: Q4 Financials
Q4 Financials • Revenues were 365 (298) MSEK, +23% • EBIT was 103 (81) MSEK (+28%) • EBIT margin of 28% (27%) • Earnings per share were 0.81 (0.67) SEK • Cash flow at 99 (100) MSEK Net sales and EBIT margin (%) 400 50% 350 45% 40% 300 35% MSEK 250 30% 200 25% 150 20% 15% 100 10% 50 5% 0 0% Q1 Q2 Q3
Slide 9: Q4 Sales Bridge
Q4 Sales Bridge 67 -3 365 298 70 2023 Organic growth Currency 2024 MSEK Q4 Change YTD Change 2023 297.8 1,296.5 Organic growth 70.5 23.7% 138.1 10.7% Currency -3.4 -1.1% -11.9 -0.9% 2024 364.8 22.5% 1,422.7 9.7% 9
Slide 10: Gross Margin per Segment
Gross Margin per Segment The gross margin was 71% compared to 76% last year The main reasons for the lower gross margins in the Pediatric and Adult Health segments are mix effects and cost of goods related inventory write-downs in BioGaia USA Q4 Q4 YTD YTD MSEK 2024 2023 2024 2023 Pediatrics 72% 78%
Slide 11: Operating Expenses (OPEX)
Operating Expenses (OPEX) OPEX +7% (+7% excluding adjustments) • Sales costs increased due to a larger proportion of direct sales through subsidiaries and strategic investments in sales and marketing activities • R&D costs increased mainly due to increased clinical study costs in the quarter • Other
Slide 12: Profit and Loss Statement
Profit and Loss Statement • Sales +23% • OPEX +7% • EBIT increased by 28% and EBIT Margin 28% Q4 Q4 YTD YTD Change Change MSEK 2024 2023 2024 2023 Sales 365 298 23% 1,423 1,297 10% EBIT Bridge Q4 Gross profit 259 225 15% 1,031 950 8% +23 - percentage of revenues 71% 76% 72% 73% OPEX -155 -145 7% -60
Slide 13: Cashflow
Cashflow • Cash Flow from Operating Activities decreased by 15% to 103 (122) MSEK. The decrease was mainly due to higher payment of taxes and change in working capital • Cash Flow for the period at 99 (100) MSEK • Cash at the end of the period at 1,224 MSEK Q4 Q4 YTD YTD MSEK 2024 2023 Change 2024 2
Slide 14: Concluding Remarks
Concluding Remarks • Net sales increased by 23% (24% excluding currency effects) • Our direct markets continue their strong performance – USA, Canada and Japan among top 5 markets • EMEA sales increased by 24% due to higher sales mainly in the Pediatrics segment. Sales increased mainly in United Kin
Slide 15: Q&A
Q&A
Slide 16: BioGaia
BioGaia.